Episode 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

Commentary
Podcast

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Katherine Peters, PhD. [LISTEN TIME: 13 minutes]

Katherine Peters, PhD

Katherine Peters, PhD

Episode 116 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 116, "Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas" features a conversation with Katherine Peters, PhD, a neurologist and neurooncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided context on a new analysis from the phase 3 INDIGO trial, a study assessing vorasidenib in patients with mutant isocitrate dehydrogenase (mIDH) 1/2 diffuse gliomas. The conversation, which occurred at the 2024 AAN Annual Meeting, covered the covered the therapeutic potential of this agent and its impacts on quality of life, neurocognition, and seizure control. Peters, an expert in the field, provided insight on the mechanism of action of vorasidenib, the added value behind the exploratory analysis, and the next steps in research. Furthermore, she provided context on the patient sample observed and why these data may hold significant weight going forward.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com

EPISODE BREAKDOWN

  • 1:05 – Mechanism of action of vorasidenib, a mIDH 1/2 inhibitor
  • 2:00 – Overview of exploratory analysis results
  • 4:20 – Significance of new data, how it adds to previous primary and secondary outcomes
  • 5:50 – Neurology News Minute
  • 8:25 – Next steps for the study and use of vorasidenib
  • 10:35 – Remaining unmet needs for patients with diffuse gliomas

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Related Videos
Charbel Moussa, MBBS, PhD
Kelly Papesh, DNP, APRN, FNP-BC
Anvi Gadani, MD
David Shprecher, DO, MSci, FAAN
Jessica Ailani, MD
Video 2 - 4 KOLs are feature in, "Changes in Presentation of Spasticity Over Time"
Video 1 - 4 KOLs are feature in, "Definition and Pathophysiology of Spasticity"
Dolores D. Santamaria, MD
© 2024 MJH Life Sciences

All rights reserved.